Evidence map›Paper›PMID 19100702›Full record

ArticleImmunity2008

CD44 mediates successful interstitial navigation by killer T cells and enables efficient antitumor immunity.

Paulus Mrass, Ichiko Kinjyo, Lai Guan Ng, Steven L Reiner, Ellen Puré, Wolfgang Weninger

Open access · bronzeAbstract read
In one paragraph

Article in Immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Review
  3. SLAMF7 (CD319) on activated CD8Cell death and differentiation · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. CD24: A Novel Target for Cancer Immunotherapy.Journal of personalized medicine · 2022
    Review
  17. Review
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Paulus MrassThe Wistar Institute, Philadelphia, PA 19104, USA.
Ichiko Kinjyo
Lai Guan Ng
Steven L Reiner
Ellen Puré
Wolfgang Weninger
Cancer Research Institute · USCentenary Institute · AULudwig Cancer Research · USThe Wistar Institute · USUniversity of Sydney · AU

Funding

Control of CD8+ Effector T Cell DifferentiationR01AI061699 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI REINER, STEVEN L · 2005 to 2015
$4.0M
Asymmetric Lymphocyte Division in the Immune ResponseR01AI076458 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI REINER, STEVEN L · 2008 to 2019
$3.7M
NIAID NIH HHS R01 AI061699NIAID NIH HHS R01 AI076458
6 · The paper itself

Abstract

Although T lymphocytes are constitutively nonadherent cells, they undergo facultative polarity during migration and upon interaction with cells presenting cognate antigen, suggesting that cell polarity might be critical for target cell destruction. Using two-photon imaging of tumor-infiltrating T lymphocytes, we found that CD44, a receptor for extracellular matrix proteins and glycosaminoglycans, was crucial for interstitial T cell navigation and, consequently, efficient tumor cell screening. CD44 functioned as a critical regulator of intratumoral movement by stabilizing cell polarity in migrating T cells, but not during target cell interactions. Stable anterior-posterior asymmetry was maintained by CD44 independently of its extracellular domain. Instead, migratory polarity depended on the recruitment of ezrin, radixin, moesin (ERM) proteins by the intracellular domain of CD44 to the posterior cellular protrusion. Our results formally demonstrate that CD44-dependent T lymphocyte locomotion within target sites represents an essential immunologic checkpoint that determines the potency of T cell effector functions.

Indexed as

AnimalsCell AdhesionCell CommunicationCell DifferentiationCell Line, TumorCell MovementCell PolarityCytoskeletal ProteinsEzrinHyaluronan ReceptorsMembrane ProteinsMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMicrofilament ProteinsCytoskeletal ProteinsEzrinHyaluronan ReceptorsMembrane ProteinsMicrofilament Proteinsmoesinradixin

Identifiers

PMID19100702
PMCPMC2757129
OpenAlexW2092997355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.